Biocompatibility of brilliant blue G in a rat model of subretinal injection
Biocompatibility of brilliant blue G in a rat model of subretinal injection
复制标题
DOI：
10.1097/iae.0b013e318030a129
复制
发表时间：
2007-04-01
影响因子：
3.3
通讯作者：
Ishibashi, Tatsuro
中科院分区：
文献类型：
--
作者：
Ueno, Akifumi;Hisatomi, Toshio;Ishibashi, Tatsuro
目的：在大鼠视网膜下注射模型中比较亮蓝G（BBG）与吲哚菁绿（ICG）和台盼蓝（TB）的毒性。方法：通过视网膜下注射染料产生视网膜脱离。通过眼科检查在 2 个月零 2 周内评估 BBG (0.25 mg/mL) 的生物相容性。将眼睛摘除并通过光、荧光以及透射电子显微镜进行分析。通过 TdT-dUTP 末端切口标记检测细胞凋亡。将结果与ICG（5 mg/mL）和TB（1 mg/mL）的结果进行比较。结果：ICG在视网膜下注射后2周引起视网膜变性和视网膜色素上皮（RPE）细胞萎缩。在内核层、外核层和 RPE 层，特别是光感受器中检测到细胞凋亡。结核病引起的视网膜变性较少，主要发生在视网膜下注射分离的区域。 2 个月零 2 周后，BBG 没有检测到任何毒性作用。在ICG和TB组中检测到细胞凋亡，主要是在光感受器中。结论：视网膜下注射染料引起视网膜细胞变性的浓度低于报道的玻璃体内注射的浓度。然而，视网膜下注射 0.25 mg/mL 的 BBG 似乎提供了令人满意的生物相容性。
Purpose: To evaluate the toxicity of brilliant blue G (BBG) compared with those of indocyanine green (ICG) and trypan blue (TB) in a rat model of subretinal injection.Methods: Retinal detachment was produced by subretinal injection of the dyes. The biocompatibility of BBG (0.25 mg/mL) was evaluated over 2 months and 2 weeks by ophthalmic examinations. The eyes were enucleated and analyzed by light, fluorescence, as well as transmission electron microscopy. Apoptotic cell death was detected by TdT-dUTP terminal nick-end labeling. The results were compared with those for ICG (5 mg/mL) and TB (1 mg/mL).Results: ICG caused retinal degeneration and retinal pigment epithelial (RPE) cell atrophy 2 weeks after subretinal injection. Apoptotic cell death was detected in the inner and outer nuclear layers and the RPE layer, especially the photoreceptors. TB caused less retinal degeneration, mainly in the area detached by the subretinal injection. BBG had no detectable toxic effects after 2 months and 2 weeks. Apoptotic cell death was detected in the ICG and TB groups, mainly in the photoreceptors.Conclusions: Subretinal injection of the dyes caused retinal cell degeneration at lower concentrations than those reported for intravitreous injection. However, subretinal injection of BBG at 0.25 mg/mL appeared to provide satisfactory biocompatibility.